The Health Resources & Services Administration (HRSA) is issuing a Request for Information (RFI) on the potential use of rebates for the 340B Drug Pricing Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and their effect on stakeholders.
Specifically, HRSA seeks information on:
- The costs of rebate models to covered entities
- Payment timing and cash flow impacts for covered entities
- The implications of rebate denials
- How rebate models would affect data collection by covered entities
- Manufacturer efforts to avoid duplicate discounts
- Reporting requirements
- The effects of a rebate model on 340B program integrity
Responses to the RFI are due March 19.
Contact Director of Policy Rob Nelb, MPH, at rnelb@essentialhospitals.org or 202.585.0127 with questions.
Author